Category Archives: Genetics

Liverpool Women’s Hospital to increase genetic testing of babies – Liverpool Echo

Liverpool Womens Hospital is to expand its ability to genetically test newborn babies 12-fold.

The NHS Foundation Trust will be able to screen all infants for inherited conditions or illnesses and plan for early treatment as part of a major new IT project.

IT firm Novosco will introduce the computing system which also contribute to a major population health programme in Liverpool - analysing genetic information by location, identifying and enabling work to prevent localised health issues.

The role of genetics in healthcare is one of the most rapidly expanding areas of development for Liverpool Womens.

It provides a regional clinical genetics service covering a population of around 2.8 million people from across Merseyside, Cheshire and the Isle of Man.

Chief executive Kathryn Thomson posted on the trusts website: To discover that you or any child you have or plan to have may be at risk of a genetic disorder which could cause disability or a rare condition is traumatic.

People are sometimes shocked and anxious and wonder what the future might hold.

They need as much information and support as possible to help them cope.

That is why the often unsung work of our clinical genetics team is so important, providing diagnosis and supporting families when they need it most.

Novosco managing director Patrick McAliskey said: We are delighted to secure this contract which will enable the trust to take genetic testing to the next level and play an important role in the identification and prevention of conditions and illnesses in new-born babies and the wider population.

Original post:
Liverpool Women's Hospital to increase genetic testing of babies - Liverpool Echo

The Genetics of Eating Disorders – Scientific American (blog)

Thirty million American women and men will struggle with eating disorders in their lifetime, and these life-threatening conditions have a higher mortality rate than any other psychiatric illness. For example, someone struggling with anorexia for five years has a 5 per cent, or one in20 chance, of dying.

While more and more people have come to understand that eating disorders are diseases of the brain, there's still awidespreadbeliefthat people with these devastating conditionsare vain, attention-seeking, or lacking in will power. But apaperjust published in Plos One makes it clear that this isn't true. The studyevaluated the genomes of95 individuals with diagnosed eating disorders andidentified 430 genes, clustered into two large groups, that are more likely to be damaged than in people without those disorders.

This adds to a growing body of research shows that eating disorders are powerful, biologically-driven illnesses. The new studysupports previous findings that the risk of developing an eating disorder is 50-80 per cent geneticthatpatientshave inherited damaged copies of genes that increase their risk of developing disordered eating. And understanding which genes are damaged can practitioners create better treatment treatment protocols.

In the PlosOne study, patients with eating disorders were clustered into two main groups. In the first, the damaged genes fell into a class of gut neuropeptides affecting that control appetite,food intakeand digestion/absorption of nutrients, making patients more likely to binge. Roughly half of this group struggled with restricted eating patterns, and the other half were binge eaters. The research confirms reports by our patients who believe their behavior is biologically driven.

The second group of patients had a cluster of genes involved in the function of the immune system and inflammation, which has long been known to suppress appetite. Patients with damaging mutations in the inflammation cluster are much more likely to have restricted-eating patterns. More research is needed to test a possible connection between eating disorders and auto-immune conditions like irritable bowel disease.

The new findings are consistent with known environmental eating disorder triggers. Faddieting, excessive exercise, or medical illness, are examples of negative energy states that have long been seen as possible eating disorder triggers. Negative energy states can set up behavioral changes like food binges or restricted food intake, triggering preexisting genetic drivers for eating disorders. Based on these findings, we argue that eating disorders are biologically driven illnesses that alter mood and behavior, similar to how the lack of thyroid hormone can result in depression in a patient with hypothyroidism.

Failure to understand the underlying causes of eating disorders creates stigma, making it less likely for those who struggle to get treatment. People with any medical condition deserve support and access to the best treatment. Someone with cancer wouldnt be denied treatment for their illness. Likewise, patients with eating disorders shouldnt feel guilty about their illness and they should have access to safe, effective treatment.

Biology isnt destiny. Eating disorders treatment is most effective if its accompanied by a general understanding that eating illnesses are biologically driven.

Lasting recovery from an eating disorder is possibleand those who struggle deserve understanding and support without guilt or judgment.

Read this article:
The Genetics of Eating Disorders - Scientific American (blog)

Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors – Business Wire (press release)

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq Copenhagen: GEN) and Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that Seattle Genetics, Inc. has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development option for tisotumab vedotin at the end of Phase I clinical development. Tisotumab vedotin, an antibody-drug conjugate (ADC) targeting tissue factor, is currently being evaluated in Phase I/II clinical studies in solid tumors. Going forward, Genmab and Seattle Genetics will co-develop and share all future costs and profits for tisotumab vedotin on a 50:50 basis.

The combination of Genmabs differentiated HuMax-TF antibody and Seattle Genetics clinically-validated antibody-drug conjugate (ADC) technology has resulted in encouraging preliminary data for tisotumab vedotin in selected solid tumors. We very much look forward to working with Seattle Genetics to further develop this exciting first-in-class ADC product, said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Our ADC partnership with Genmab has generated promising Phase I/II data for tisotumab vedotin in patients with recurrent cervical cancer. As Seattle Genetics opts into co-development of this clinical program, we add another potential product to our strong pipeline, said Clay Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. Together with Genmab, we look forward to advancing tisotumab vedotin for the treatment of solid tumors.

Preliminary data from the ongoing Phase I/II study of tisotumab vedotin in solid tumors (GEN701) were announced in June 2017, demonstrating antitumor activity and manageable safety in recurrent cervical cancer patients. This announcement can be found here. Updated preliminary data from the Phase I/II study will be presented in an oral presentation at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid (Spain), September 8-12, 2017.

Todays news does not impact the 2017 financial guidance issued by Genmab on May 10, 2017.

About the collaboration

In October 2011, Genmab and Seattle Genetics, Inc. entered into a commercial license and collaboration agreement for ADCs. Under the agreement, Genmab was granted rights to utilize Seattle Genetics ADC technology with its HuMax-TF antibody. Seattle Genetics was granted rights to exercise a co-development and co-commercialization option at the end of Phase I clinical development for tisotumab vedotin. With todays news Seattle Genetics exercises its option to co-develop tisotumab vedotin and the companies will share all future costs and profits for the product on a 50:50 basis. Seattle Genetics will be responsible for commercialization activities in the US, Canada, and Mexico, while Genmab will be responsible for commercialization activities in all other territories. Each party has the option to co-promote by employing up to 40 percent of the sales effort in the other partys territories.

About tisotumab vedotin

Tisotumab vedotin is an antibody-drug conjugate (ADC) composed of a human antibody that binds to tissue factor (TF) and Seattle Genetics ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE). TF is a protein involved in tumor signaling and angiogenesis. Based on its high expression on many solid tumors and its rapid internalization, TF was selected as a target for an ADC approach. Tisotumab vedotin is in Phase I/II clinical studies for solid tumors.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody platform for generation of bispecific antibodies, and the HexaBody platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit http://www.genmab.com.

About Seattle Genetics

Seattle Genetics is an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer. The companys industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS (brentuximab vedotin), the companys lead product, in collaboration with Takeda Pharmaceutical Company Limited, is the first in a new class of ADCs commercially available globally in 67 countries for relapsed classical Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL). Seattle Genetics is also advancing enfortumab vedotin, an ADC for metastatic urothelial cancer, in a planned pivotal trial in collaboration with Astellas. Headquartered in Bothell, Washington, Seattle Genetics has a strong pipeline of innovative therapies for blood-related cancers and solid tumors designed to address significant unmet medical needs and improve treatment outcomes for patients. The company has collaborations for its proprietary ADC technology with a number of companies including AbbVie, Astellas, Bayer, Celldex, Genentech, GlaxoSmithKline and Pfizer. More information can be found at http://www.seattlegenetics.com

Forward Looking Statement for Genmab

This Company Announcement contains forward looking statements. The words believe, expect, anticipate, intend and plan and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmabs most recent financial reports, which are available on http://www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; the DuoBody logo; the HexaBody logo; HuMax; HuMax-CD20; DuoBody; HexaBody and UniBody. Arzerra is a trademark of Novartis AG or its affiliates. DARZALEX is a trademark of Janssen Biotech, Inc.

Forward Looking Statement for Seattle Genetics

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of tisotumab vedotin and its possible benefits and uses, and planned development activities including future clinical trials. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the inability to show sufficient activity and the risk of adverse events as tisotumab vedotin advances in clinical trials and regulatory actions. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended June 30, 2017 filed with the Securities and Exchange Commission.Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Original post:
Genmab and Seattle Genetics to Co-develop Tisotumab Vedotin for Solid Tumors - Business Wire (press release)

Genetics put some older women at higher risk than men for Alzheimer’s – USC News

White women whose genetic makeup puts them at higher risk for Alzheimers disease are more likely than white men to develop the disease during a critical 10-year span in their lives, according to a study headed by Keck School of Medicine of USC researchers.

The findings from one of the worlds largest big-data studies on Alzheimers counter long-held beliefs about who is at greatest risk for the disease and when, suggesting new avenues for clinical trials.

Study results show genetically vulnerable 55- to 85-year-old white men and women have the same odds of developing the memory-erasing disease. One exception: From their mid-60s to mid-70s, these women still face significantly higher risk. That may provide clues to disease causes and potential interventions among these women.

Our discovery is important because it highlights how clinical trials could be weighted toward women a susceptible part of the population to help scientists more rapidly identify effective drug interventions to slow or cure Alzheimers, said Arthur Toga, director of the USC Stevens Neuroimaging and Informatics Institute at the Keck School of Medicine among the nations leaders in innovative scientific discovery.

The study was published Aug. 28 in the Journal of the American Medical Association Neurology. It included data from 57,979 North Americans and Europeans in the Global Alzheimers Association Interactive Network (GAAIN). This big-data project provides scientists around the world with shared data and sophisticated analysis tools to address a disease that makes up about 65 percent of the 47 million cases of dementia worldwide.

The results contradict a seminal 20-year-old study that found women with one copy of ApoE4, a gene variant linked to Alzheimers, were diagnosed with the disease 50 percent more often than men with the same genetic profile.

The findings presented in the USC-led study expand the number of participant data by ninefold and indicate the critical decade falls between 65 and 75, more than 10 years after the start of menopause. Previous studies in animals and humans have reported a relationship between ApoE4, menopause and cognitive decline.

So much work has been dependent on one 1997 finding, but with tools like GAAIN, we now have the ability to reinvestigate with increased statistical power, Toga said.

The new findings are significant because almost two-thirds of the more than 5 million Americans now with Alzheimers disease today are women.

The new findings are significant because almost two-thirds of the more than 5 million Americans now living with Alzheimers disease are women, according to the Alzheimers Association.

Many attribute the imbalance in disease risk to the fact that women, on average, live longer than men. However, a growing body of evidence suggests other reasons also contribute to the difference. For instance, men have higher rates of heart disease and stroke. So, men who live longer may be healthier than women of the same age and may face less risk of developing Alzheimers, according to the USC-led study.

In the future, doctors who want to prevent Alzheimers may intervene at different ages for men and women, said Judy Pa, co-author of the study and an assistant professor of neurology at the USC Stevens Neuroimaging and Informatics Institute.

Menopause and plummeting estrogen levels, which on average begins at 51, may account for the difference, Pa said. However, scientists still dont know what is responsible. Researchers need to study women 10, 15 or even 20 years before their most vulnerable period to see if there are any detectable signals to suggest increased risk for Alzheimers in 15 years.

Only some women are at increased risk of developing Alzheimers in their mid-60s to mid-70s compared to men. To find out, women could have their DNA analyzed. However, Pa cautions that genetic testing for the ApoE4 variant is no crystal ball.

There is controversy in terms of whether people should know their ApoE status because it is just a risk factor, Pa said. It doesnt mean youre going to get Alzheimers disease. Even if you carry two copies of ApoE4, your chances are greatly increased, but you could still live a long life and never have symptoms.

Even if some women discover they are at heightened risk, they can improve their odds by making life changes.

Get more exercise. Work out your mind, especially in old age.

Judy Pa

Get more exercise. Work out your mind, especially in old age, Pa said. Pick up hobbies that are cognitively or physically challenging. Reduce processed sugar intake because its linked to obesity, which is associated with many chronic diseases.

Alzheimers disease is the fifth-leading cause of death for Americans 65 and older, but it may one day outpace the nations top two killers heart disease and cancer. Alzheimers-related deaths increased by nearly 39 percent between 2000 and 2010 while heart disease-related deaths declined 31 percent and cancer deaths fell 32 percent, according to the Centers for Disease Control and Prevention.

Because Alzheimers disease has a huge impact on lifelong health, USC has more than 70 researchers dedicated to the prevention, treatment and potential cure of the memory-erasing disease. Big data projects like this require experts across disciplines computer science, biology, pathophysiology, imaging and genetics to coordinate.

For this study, the researchers examined data from 27 different studies that assessed participants ApoE gene variation, as well as characteristics such as sex, race, ethnicity, diagnosis (normal, mild cognitive impairment or Alzheimers disease) and age at diagnosis.

The records of nearly 58,000 people were scrutinized. Meta-analyses were performed on 31,340 whites who received clinical diagnoses sometime between ages 55 and 85.

The proportion of minorities was so small that analysts could not draw statistically significant conclusions about their disease risk. Because of this, the study focused on whites only.

Most of the archives around the world have insufficient numbers of underrepresented groups, Toga said. One of the take-home messages from our study is people of all races and ethnicities need to be involved in Alzheimers clinical trials because this disease is a problem that affects all of us.

The current findings need to be confirmed in more diverse study populations.

USC is working to build more diverse population studies related to Alzheimers. Established in 1984, the Alzheimer Disease Research Center at the Keck School of Medicine reaches out to communities in the greater Los Angeles area to educate the citys diverse population about Alzheimers and the clinical trials they might be interested in joining. Previous studies, for example, have focused on Latinos.

Historically, women have not been adequately represented in clinical trials, especially in studies on heart disease. Women need to be represented equally to men or even overrepresented, Pa said.

The bottom line is women are not little men, Pa said. A lot more research needs to target women because gender-specific variations can be so subtle that scientists often miss them when they control for gender or use models to rule out gender differences. Most research today is ignoring a big part of the equation.

The study was made possible because of lead author Scott Neu, a leader in the development of a federated approach to analyzing metadata and assistant professor of research at the Laboratory of Neuro Imaging at the Keck School of Medicine.

GAAIN the free resource we created in conjunction with the Alzheimers Association allows anyone to explore data sets around the world and conduct preliminary analyses to test scientific hypotheses, Neu said. Our goal is to connect scientists with those who have collected data to create new collaborations to further research and understanding of Alzheimers disease.

Analysts excluded people with a history of stroke, cerebrovascular disease, abnormal proteins that contribute to Parkinsons disease and dementia, gene mutations leading to higher levels of toxic amyloid brain plaques and any known neurological diseases.

Scientists did not adjust for known Alzheimers risk factors such as education, family history of Alzheimers or dementia because that information was not provided in all data sets. They also were unable to adjust for sex-dependent differences such as cigarette smoking, hormonal changes with age and alcohol usage.

The study was supported by the Alzheimers Association through the Global Alzheimers Association Interactive Network initiative (GAAIN-14-244631) via a $5 million grant and a portion of two National Institutes of Health grants: $12 million from Big Data to Knowledge (U54-EB020406) and $5 million from neuroimaging and genetics (P41-EB015922).

More stories about: Alzheimer's Disease, Research

Go here to read the rest:
Genetics put some older women at higher risk than men for Alzheimer's - USC News

Hospital to boost genetic testing for newborn babies – Belfast Telegraph

Hospital to boost genetic testing for newborn babies

BelfastTelegraph.co.uk

One of the UK's largest women's hospitals is to increase its ability to genetically test newborn babies 12-fold.

http://www.belfasttelegraph.co.uk/news/northern-ireland/hospital-to-boost-genetic-testing-for-newborn-babies-36079324.html

http://www.belfasttelegraph.co.uk/news/northern-ireland/article36079323.ece/c3338/AUTOCROP/h342/PANews%20BT_P-013b5e7c-4e66-4b0a-b8d6-04b3c11abd37_I1.jpg

One of the UK's largest women's hospitals is to increase its ability to genetically test newborn babies 12-fold.

Liverpool Women's NHS Foundation Trust will be able to screen all infants for inherited conditions or illnesses and plan for early treatment as part of a major new IT project.

It will also contribute to a major population health programme in Liverpool analysing genetic information by location, identifying and enabling work to prevent localised health issues.

IT firm Novosco will introduce the computing system.

Novosco managing director Patrick McAliskey said: "We are delighted to secure this contract which will enable the trust to take genetic testing to the next level and play an important role in the identification and prevention of conditions and illnesses in new-born babies and the wider population."

This role of genetics in healthcare is one of the most rapidly expanding areas of development for Liverpool Women's.

It provides a regional clinical genetics service based at Alder Hey Hospital, covering a population of around 2.8 million people from across Merseyside, Cheshire and the Isle of Man, chief executive Kathryn Thomson posted on the trust's website.

She added: "To discover that you or any child you have or plan to have may be at risk of a genetic disorder which could cause disability or a rare condition is traumatic.

"People are sometimes shocked and anxious and wonder what the future might hold.

"They need as much information and support as possible to help them cope.

"That is why the often unsung work of our clinical genetics team is so important, providing diagnosis and supporting families when they need it most."

Liverpool Women's NHS Foundation Trust specialises in the health of women and their babies - both within the hospital and in the community. It is one of only two such specialist trusts in the UK - and the largest women's hospital of its kind.

Novosco is an IT infrastructure and managed cloud computing company and employs over 150 people. It has its headquarters in Belfast, with offices in Manchester, Dublin, and Cork.

See the original post here:
Hospital to boost genetic testing for newborn babies - Belfast Telegraph

New Genetics: The Gold Seal of Approval – Cannabis Now

Nightmare Cookies | Photos Ron Goldman via Stock Pot Images

While youve probably never encountered strains like Gorilla Grip or Nightmare Cookies, Goldman and a select group of other growers have been diligently laboring over trial gardens scanning them for anomalies and difficulties or possibly the next cannabis superstar like Northern Lights or Jack Herer.

I really like pushing the boundaries to get plants to reach their full genetic potential, he says.

Strain: Frozen Tangerines

A cannabis cultivator with overfour decades of experience, Goldmans initial farming experience began as a grower of greenhouse produce in the 1980s. More recently,his talents have been sought after by a number of marijuana seed breeders looking totest out new creations.

The same way that most manufacturers put their products through rigorous testing, says Goldman, cannabis seeds need to be tested toobefore theyre released to the world.

Because breeders are basically putting their reputations on the line every time they release a newly developed strain, testers like Goldman are absolutely essential to the process. The seed sellers that he consults for want to hear all the pros and cons of their new strains how they handle heat, synthetic versus organic fertilizers or small versus large habitats. They want a full picture of the plants inherent strengths, weaknesses and peculiarities to know whether its back to the drawing board or ready for consumer release.

Strain: Purple Frog

With every trial run, Goldman creates a detailed grow log from the time seeds germinate all the way through harvest. Being an avid photographer and a teacher of photography besides all of his very detailed scientific methodology is accompanied by close photo documentation week after week as the plants mature.

Ill document the structure of the plant and flowers. Looking at things like flower density and calyx to leaf ratio as well as yield and cannabinoid levels.

Some of Goldmans most recent work has been with Sin City Seeds, testing potential new releases such as Nightmare Cookies, a cross of White Nightmare and Platinum Girl Scout Cookies. He says its not only a beautiful plant with rich colors but at 26 percent THC, it packs a potent punch.

Strain: West Seattle

With Washington state now allowing medical and recreational cultivation, says Goldman, I can legally put together my passion for photography with my passion for growing.

The following photos were all taken from Goldmans medical cannabis test gardens and are strains we hope the public will soon have a chance to sample.

Originally published in Issue 18 of Cannabis Now. LEARN MORE

TELL US,does cannabis breeding interest you?

See the article here:
New Genetics: The Gold Seal of Approval - Cannabis Now

In Brief This Week: Qiagen, Clinical Genomics, Streck, Oxford Genetics, Isohelix – GenomeWeb

Qiagen and Clinical Genomics announced a partnership to use the PAXGene Blood ccfDNA Tube for collection and handling of blood samples in Clinical Genomics' Colvera colorectal cancer recurrence assay workflow. The PAXGene Blood ccfDNA system was developed by PreAnalytix, a Qiagen/Becton Dickinson joint venture. Colvera is a PCR-based assay that detects hypermethylated BCAT1 and IKZF1 DNA in the blood of patients.

Registering provides access to this and other free content.

Already have an account?.

Go here to see the original:
In Brief This Week: Qiagen, Clinical Genomics, Streck, Oxford Genetics, Isohelix - GenomeWeb

Genetics research gives farmers larger tomatoes – The Albany Herald

ATHENS Ever wonder how that slice of tomato on your summer BLT got to be so perfectly bread-sized?

kAmv6?6E:4:DED 2E E96 &?:G6CD:EJ @7 v6@C8:2 92G6 7@F?5 E96 86?6 G2C:2?ED E92E 4@?EC@= 2 E@>2E@D D:K6] %96J AF3=:D965 E96:C 7:?5:?8D C646?E=J 😕 E96 @A6?2446DD ;@FC?2= !{~$ v6?6E:4D]k^Am

kAm!C@76DD@C tDE96C G2? 56C z?22A H9@ 92D DA6?E >F49 @7 96C 42C66C H@C<:?8 E@ F?56CDE2?5 E96 86?6E:4 D9:7ED E92E 92G6 @44FCC65 36EH66? 2?46DEC2=[ H:=5 E@>2E@ G2C:6E:6D 2?5 >@56C?[ 4F=E:G2E65 E@>2E@6D 92D 96=A65 E@ A:?A@:?E 2?@E96C 86?6 E92E C68F=2E6D E96 D:K6 @7 E96 E@>2E@D :?5:G:5F2= 46==D[ H9:49 😕 EFC? 96=AD E@ C68F=2E6 E96 D:K6 @7 E96 @G6C2== 7CF:E]k^Am

kAm%96 A24E:?8 @E96C :>A@CE2?E BF2=:E:6D DF49 2D 5:D62D6 C6D:DE2?46 2?5 7=2G@C[ D2:5 G2? 56C z?22A[ 2 AC@76DD@C 😕 E96 56A2CE>6?E @7 9@CE:4F=EFC6 2?5 E96 x?DE:EFE6 @7 !=2?E qC665:?8[ v6?6E:4D 2?5 v6?@>:4D 2E &vp]k^Am

kAm(96? 9F>2?D 7:CDE 3682? 4F=E:G2E:?8 E96 H:=5 E@>2E@ 😕 E96 p?562? >@F?E2:? C68:@?D @7 t4F25@C 2?5 }@CE96C? !6CF[ E96J 4@?E:?F2==J D6=64E65 A=2?ED E92E AC@5F465 =2C86C 7CF:ED]k^Am

kAm}@H[ E9@FD2?5D @7 J62CD =2E6C[ E@>2E@6D @? E96 >2C<6E 42? H6:89 `[___ E:>6D >@C6 E92? E96 7CF:ED @7 E96:C 2?46DE@CD] '2? 56C z?22A 2?5 96C C6D62C49 E62> :?G6DE:82E65 2 86?6 E96J ?2>65 r6== $:K6 #68F=2E@C[ @C r$#[ E92E 3@@DED 7CF:E H6:89E 3J :?4C62D:?8 E96 D:K6 @7 E96 :?5:G:5F2= 46==D 😕 E96 7=6D9J A2CE @7 E96 E@>2E@]k^Am

kAmr@>A2C65 E@ H:=5 E@>2E@6D[ 5@>6DE:42E65 G2C:6E:6D 42CCJ 2 >FE2E:@? 😕 E96 r$# 86?6 E92E 27764ED E96 H2J E@>2E@ 46==D 56G6=@A 367@C6 E96J C:A6? 2?5 72== @77 E96 A=2?E] %96 G2C:2E:@? @C:8:?2E65 😕 E96 496CCJ E@>2E@ 3FE ?@H 2AA62CD 😕 2== =2C86 4F=E:G2E65 E@>2E@ G2C:6E:6D]k^Am

kAm%96 ?6H DEF5J 6IA2?5D @? AC6G:@FD C6D62C49 E92E 925 :56?E:7:65 E96 =@42E:@? @7 r$# 2E E96 3@EE@> @7 49C@>@D@>6 `` 2D @?=J 2 D>2== 86?6E:4 4@?EC:3FE@C E@ E@>2E@ H6:89E]k^Am

kAm%96 EC2?D7@C>2E:@? @7 E96 E:?J[ 36CCJ=:<6 7CF:E @7 H:=5 E@>2E@6D :?E@ E96 3667DE622 E@>2E@6D 8C@H? 3J 72C>6CD E@52J :?G@=G65 E96 56G6=@A>6?E @7 2 ?6H >FE2E:@? E@ DFAA@CE E96 492?86 😕 7F?4E:@? @7 E96 r$# 86?6] {2C86 7CF:E C6BF:C65 >2?J >@C6 >FE2E:@?D 😕 @E96C 86?6D E@ 2==@H E96 A=2?E E@ 42CCJ 2?5 DFAA@CE :ED ?6H 3@F?EJ]k^Am

kAm%96C6 H2D D=@H D6=64E:@? 7@C =2C86 7CF:E 3J A6@A=6 3642FD6[ @7 4@FCD6[ :7 E96 E@>2E@ 7CF:E 8C6H E@@ 3:8 7@C E96 A=2?E[ :E H@F=5 4@==2AD6 E96 A=2?E 2?5 E92E H@F=5 36 2 56256?5 A=2?E[ D2:5 G2? 56C z?22A] x7 E96 7CF:E 😀 E@@ =2C86 7@C E96 A=2?E E96? :E 42? @?=J >2<6 E92E @?6 7CF:E 367@C6 :E 4@==2AD6D] p?J 72C>6C H@F=5 D2J[ %92ED ?@ 8@@5[ 2?5 E@DD :E @FE]k^Am

kAmxE E@@< E9@FD2?5D @7 J62CD 7@C 72C>6CD E@ 3C665 E@>2E@ A=2?ED E@ AC@5F46 E96 7CF:E H6 FE2E:@?D E92E =65 E@ A=2?ED E92E 4@F=5 DFAA@CE =2C86C E@>2E@6D]k^Am

kAmu@C 7CF:E H6:89E[ x E9:?< H6 92G6 ;FDE D4C2E4965 E96 DFC7246 E96C6D DE:== 2 =@E E92E H6 5@?E

kAm'2? 56C z?22AD E62>D ;@FC?2= 2CE:4=6 😕 !{~$ v6?6E:4D 😀 2G2:=23=6 2E 9EEAi^^;@FC?2=D]A=@D]@C8^A=@D86?6E:4D^2CE:4=6n:5l`_]`bf`^;@FC?2=]A86?]`__ehb_] ~E96C 4@==23@C2E@CD 2C6 8C25F2E6 DEF56?E ": |Fj A@DE5@4E@C2= D49@=2CD +6;F? wF2?8[ |2?@92C r92@D]k^Am

kAmW%96 DE277 @7 !{~$ v6?6E:4D 4@?EC:3FE65 E@ E9:D C6=62D6]Xk^Am

kAmk6>m|6CC:EE |6=2?4@? 😀 2 ?6HD 65:E@C H:E9 E96 &?:G6CD:EJ @7 v6@C8:2 r@==686 @7 p8C:4F=EFC2= 2?5 t?G:C@?>6?E2= $4:6?46D]k^6>mk^Am

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

Get Breaking News alerts from the Albany Herald delivered to your email.

Get the Local News headlines from the Albany Herald delivered daily to your email.

Get the Sports headlines from the Albany Herald delivered daily to your email.

Here is the original post:
Genetics research gives farmers larger tomatoes - The Albany Herald

Genetics for everyone – The Boston Globe

Illustration by cristina span/for the boston globe

The Greeks asked their oracles to predict future fortunes and future losses. The Romans studied the entrails of sacrificed animals for similar reasons. In modern-day medicine, though, soothsayers come in the form of genetic tests.

Ever since the human genome was sequenced almost 15 years ago, tens of thousands of genetic tests have flooded the marketplace. By analyzing someones DNA, often through a blood sample or cheek swab, these tests promise to foretell whether a patient is prone to certain cancers, blessed with the potential to become a star soccer player, or at an elevated risk of having an opioid addiction.

Advertisement

These types of genetic tests are finding an eager audience. The North American genetic testing market, already the largest in the world, was worth $11.9 billion in 2016, by one estimate, and is expected to grow at more than 15 percent a year for the foreseeable future. Companies such as LabCorp, which offer genetic tests via doctor recommendations, and the healthcare giant Roche have moved aggressively into the field. The company 23andMe, a household name because of its ancestry tests, sells health-related tests directly to consumers.

But for a source of medical information to be legally sold in the United States, just how accurate does it need to be?

Like a prediction from a crystal ball, genetic test results are sometimes wrong. Some tests that predict the likelihood a young pregnant woman will have a child with a genetic condition such as Down syndrome may only be correct only 60 percent of the time. Most genetic tests, and many other lab tests, go unvetted by the Food and Drug Administration. That means these tests may not undergo any independent review to make sure they accurately pick up the disease or genetic conditions they claim to be seeking.

Using the worlds first portable DNA lab to sequence beer is a cool thing to do.

The FDA has been wrestling for years with whether and how to do more. During the Obama administration, the agency proposed a new set of draft limits on a whole class of tests, and then put them on hold immediately after Donald Trumps election. This spring, the FDA gave 23andMe permission to market genetic screenings for susceptibility to Alzheimers, Parkinsons, and other conditions. It was the first time the agency blessed direct-to-consumer tests for genetic health risks.

While the debate over genetic testing often follows a pattern familiar from countless other industries business groups want less regulation, and consumer advocates favor more it also raises more cosmic questions: Is a medical test just a piece of information? Or is it something more, if its result leads to dramatic or irreversible action such as chemotherapy or an abortion? And if a data point is factually suspect, or ripe for misinterpretation, when and how should it be offered to consumers?

Advertisement

Especially if regulators stand aside, Americans may soon be swimming in even more tests that vary greatly in their reliability. Yet for some people contemplating a current ailment or their future well-being, getting an answer even an unreliable one may be better than no answer at all.

Especially for people expecting a baby, genetic tests can be hard to resist. I think we all are wanting to know our child doesnt have something... we want them to be healthy, said Mischa Livingstone, a filmmaker and professor who lives in California. Without asking for it, his pregnant wife, Jessica, was given a genetic test that predicted a 99 percent chance their child would have Turner syndrome, a genetic condition that can lead to short stature, heart defects, and other symptoms. But genetic tests for Turner are more often wrong than right a fact the couple didnt know at the time.

They were devastated, and immediately went for more invasive testing, which showed the fetus was fine. But their sense of dread didnt lift until their daughter, now 2 1/2, was born perfectly healthy.

Despite the heartache a faulty genetic test result caused, Livingstone says hed consider asking for one again. I think it feeds into that need for certainty, he said.

Both individuals and society as a whole are intolerant of the unknown, medical sociologists say.

Long before genetic screenings, there was a critical relationship between lab tests and medical treatment. Doctors often wont prescribe drugs or treatment without a positive test result. Insurance payments are rarely processed without diagnostic codes. The rise of genetic testing wont change, and may even amplify, that dynamic.

While some diagnoses may still carry social stigma think schizophrenia, for example they more often may confer legitimacy. Having a gene for alcoholism, for example, can make people view the problem as biological, as opposed to a character flaw. For patients, genetic tests promote a therapeutic optimism a hope that they can be treated and cured for an immediate problem or a future one, according to Michael Bury, professor emeritus at Royal Holloway, University of London, who studies society and illness.

A test alone can feel like a step forward. Undergoing a screening, said Natalie Armstrong, professor of healthcare improvement research at the University of Leicester, can make people feel that at least they are doing something proactive.

Interestingly, one study indicated that certain direct-to-consumer genetic tests dont affect users behavior or anxiety levels, bolstering the argument that people may use the information as data points, not a surefire prediction of their own fate.

Many bioethicists are unpersuaded. On an individual basis, it is tempting to discount the pitfalls of a little extra information, says Beth Peshkin, an oncology professor and genetic counselor at Georgetown Lombardi Comprehensive Cancer Center in Washington, D.C. But on a population level the implications of inaccurate results can be costly and, sometimes, deadly.

One of the most cited examples of this harm is from a 2008 genetic test for ovarian cancer that misdiagnosed women, some of whom had their ovaries removed unnecessarily before the test was pulled from the market. Because test makers do not have to report when a test turns out to be wrong in fact many people may never know when a test result is a false positive or negative FDA officials have said it has been almost impossible to assess the overall harm from all unregulated tests.

Cost is another concern that may arise from the overuse of genetic tests that proliferate without meaningful oversight. Tests often beget more tests that cost an ever-escalating amount of money. Enough testing, will invariably pick up something abnormal in a patient, even though it may not harm them, some experts believe.

In some ways its easy for us to try and find something definitive and act on that even though it has nothing to do with what is wrong with the patient, said H. Gilbert Welch, a cancer research at Dartmouth College who has written extensively on the dangers of overtesting. Genetics is an amazing tool... but to what extent does that data predict something that you care about? Is it useful knowledge?

Get This Week in Opinion in your inbox:

Globe Opinion's must-reads, delivered to you every Sunday.

The American Clinical Laboratory Association, the key trade group for genetic test makers, and other advocates of lighter regulation argue that bad tests are rare, and that its more important for the free market to allow innovation. With more tests in place to identify disease, cures come next, they say.

So far, the public has shown little concern about the fallout of genetic testing. While a 2016 poll showed only 6 percent of American adults have undergone genetic testing, 56 percent of them said they would want to if it could predict cancer or a disease like Alzheimers. Most Americans, the poll found, believe genetic tests for predicting disease are mostly accurate and reliable.

Safety advocates best chance to tighten regulation may have already passed. The world of genetic testing becomes more free-wheeling and consumer-driven all the time. By one industry estimate, 10 new genetic testing products enter the market each day. Despite considerable skepticism from medical experts, new apps purport to use data from gene sequencing to develop personalized diet plans and fitness routines.

The FDAs now-shelved rules would have classified genetic and other tests according to how much harm they could cause if their result was wrong. For example, a new genetic test for colon cancer, which requires intrusive and costly treatment, likely would have been subject to full FDA review; the maker of a test that predicts mere baldness might only have had to register it with the agency and report any known problems with it. Under the Trump administration, the agency appears less likely to draw such distinctions or impose new restrictions at all.

People want answers soon, and their inclination is to believe what appears to be solid, unassailable medicine, said Robert Klitzman, a Columbia University bioethicist. Individuals will need to evaluate these tests carefully. The notion of being able to tell your fortune has great lure. But its a little bit of hubris. We still dont know so much.

Genetic testing, still in its infancy, promises a measure of clarity about the future of our bodies. But as genetic science rapidly evolves, that modern-day crystal ball raises vexing new questions and creates its own kind of uncertainty.

View post:
Genetics for everyone - The Boston Globe

Drilling Down Into Myriad Genetics, Inc. (MYGN) – StockNewsJournal

Myriad Genetics, Inc. (MYGN) is an interesting player in the Services space, with a focus on Research Services. The stock has been active on the tape, currently trading at $29.52, up from yesterdays close by 0.92%. Given the stocks recent action, it seemed like a good time to take a closer look at the companys recent data.

Fundamental Analysis

This company has been competing with others in the Services space and offers its own combination of interesting factors Myriad Genetics, Inc. (MYGN) currently trades with a market capitalization of $2.03 Billion. That value represents a market adjusting for revenues that have been growing by 7.56 % on a quarterly year/year basis as of the companys last quarterly report.

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For MYGN, the company currently has $102.4 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $100.1 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $0.21 on a per share basis this quarter. Perhaps, that suggests something about why 96.67% of the outstanding share supply is held by institutional investors.

Technical Analysis

Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stocks movement on the chart, Myriad Genetics, Inc. recorded a 52-week high of $29.52. It is now trading 0% off that level. The stock is trading $25.76 its 50-day moving average by -3.76%. The stock carved out a 52-week low down at $15.15.

In recent action, Myriad Genetics, Inc. (MYGN) has made a move of +25.83% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is outperforming the S&P 500 by 27.56, and its gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 31.15% with $67.78 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of MYGN.

Read the original post:
Drilling Down Into Myriad Genetics, Inc. (MYGN) - StockNewsJournal